<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p161" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_161{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_161{left:306px;bottom:30px;}
#t3_161{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_161{left:346px;bottom:30px;}
#t5_161{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_161{left:517px;bottom:30px;}
#t7_161{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_161{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_161{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_161{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_161{left:35px;bottom:777px;letter-spacing:0.14px;word-spacing:0.05px;}
#tc_161{left:35px;bottom:754px;letter-spacing:0.07px;word-spacing:-0.98px;}
#td_161{left:35px;bottom:731px;letter-spacing:0.13px;word-spacing:0.05px;}
#te_161{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:0.09px;}
#tf_161{left:462px;bottom:715px;}
#tg_161{left:468px;bottom:707px;letter-spacing:-0.06px;word-spacing:0.25px;}
#th_161{left:35px;bottom:684px;letter-spacing:0.04px;word-spacing:-1.08px;}
#ti_161{left:35px;bottom:661px;letter-spacing:0.14px;word-spacing:0.04px;}
#tj_161{left:35px;bottom:638px;letter-spacing:0.05px;word-spacing:0.13px;}
#tk_161{left:35px;bottom:614px;letter-spacing:0.12px;word-spacing:-0.49px;}
#tl_161{left:35px;bottom:591px;letter-spacing:0.05px;word-spacing:0.13px;}
#tm_161{left:35px;bottom:552px;letter-spacing:0.15px;word-spacing:0.04px;}
#tn_161{left:35px;bottom:529px;letter-spacing:0.02px;}
#to_161{left:452px;bottom:536px;letter-spacing:0.1px;}
#tp_161{left:497px;bottom:529px;letter-spacing:0.1px;word-spacing:0.09px;}
#tq_161{left:35px;bottom:506px;letter-spacing:0.03px;word-spacing:0.16px;}
#tr_161{left:35px;bottom:482px;letter-spacing:0.07px;word-spacing:-0.15px;}
#ts_161{left:35px;bottom:459px;letter-spacing:0.15px;word-spacing:0.03px;}
#tt_161{left:397px;bottom:467px;letter-spacing:-0.01px;}
#tu_161{left:420px;bottom:459px;letter-spacing:0.18px;word-spacing:0.01px;}
#tv_161{left:35px;bottom:436px;letter-spacing:0.06px;word-spacing:-0.48px;}
#tw_161{left:317px;bottom:436px;}
#tx_161{left:332px;bottom:436px;letter-spacing:0.14px;word-spacing:0.05px;}
#ty_161{left:35px;bottom:413px;letter-spacing:0.06px;word-spacing:0.12px;}
#tz_161{left:35px;bottom:390px;letter-spacing:0.03px;word-spacing:-0.05px;}
#t10_161{left:35px;bottom:366px;letter-spacing:0.16px;word-spacing:0.03px;}
#t11_161{left:539px;bottom:366px;}
#t12_161{left:555px;bottom:366px;}
#t13_161{left:35px;bottom:343px;letter-spacing:0.31px;}
#t14_161{left:81px;bottom:351px;letter-spacing:-0.01px;}
#t15_161{left:35px;bottom:303px;letter-spacing:0.11px;word-spacing:0.08px;}
#t16_161{left:35px;bottom:280px;letter-spacing:0.05px;word-spacing:0.01px;}
#t17_161{left:35px;bottom:256px;letter-spacing:0.03px;word-spacing:0.15px;}
#t18_161{left:35px;bottom:233px;word-spacing:0.19px;}
#t19_161{left:247px;bottom:241px;letter-spacing:-0.01px;}
#t1a_161{left:270px;bottom:233px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1b_161{left:35px;bottom:210px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1c_161{left:35px;bottom:187px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t1d_161{left:178px;bottom:194px;letter-spacing:-0.01px;}
#t1e_161{left:202px;bottom:187px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1f_161{left:35px;bottom:163px;letter-spacing:0.19px;}
#t1g_161{left:268px;bottom:163px;}
#t1h_161{left:284px;bottom:163px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1i_161{left:35px;bottom:140px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1j_161{left:455px;bottom:140px;}
#t1k_161{left:471px;bottom:140px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1l_161{left:35px;bottom:117px;letter-spacing:0.09px;word-spacing:-0.77px;}
#t1m_161{left:35px;bottom:94px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1n_161{left:35px;bottom:71px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1o_161{left:329px;bottom:71px;}
#t1p_161{left:345px;bottom:71px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1q_161{left:618px;bottom:777px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1r_161{left:893px;bottom:777px;}
#t1s_161{left:909px;bottom:777px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1t_161{left:618px;bottom:754px;letter-spacing:0.08px;word-spacing:-0.82px;}
#t1u_161{left:618px;bottom:731px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1v_161{left:618px;bottom:707px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1w_161{left:618px;bottom:667px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1x_161{left:618px;bottom:645px;letter-spacing:0.05px;word-spacing:-0.42px;}
#t1y_161{left:618px;bottom:622px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1z_161{left:618px;bottom:599px;letter-spacing:0.08px;word-spacing:0.11px;}
#t20_161{left:618px;bottom:575px;letter-spacing:0.12px;word-spacing:-0.76px;}
#t21_161{left:802px;bottom:583px;letter-spacing:0.1px;}
#t22_161{left:847px;bottom:575px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t23_161{left:618px;bottom:552px;letter-spacing:0.04px;word-spacing:0.15px;}
#t24_161{left:618px;bottom:529px;letter-spacing:0.09px;word-spacing:0.09px;}
#t25_161{left:618px;bottom:506px;letter-spacing:-0.04px;}
#t26_161{left:684px;bottom:513px;letter-spacing:-0.01px;}
#t27_161{left:708px;bottom:506px;letter-spacing:0.1px;word-spacing:0.08px;}
#t28_161{left:618px;bottom:482px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t29_161{left:618px;bottom:459px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2a_161{left:618px;bottom:436px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2b_161{left:618px;bottom:413px;letter-spacing:0.03px;word-spacing:0.16px;}
#t2c_161{left:618px;bottom:390px;letter-spacing:0.27px;}
#t2d_161{left:662px;bottom:390px;}
#t2e_161{left:678px;bottom:390px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t2f_161{left:1034px;bottom:390px;}
#t2g_161{left:1050px;bottom:390px;letter-spacing:0.37px;word-spacing:-0.19px;}
#t2h_161{left:618px;bottom:366px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2i_161{left:618px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2j_161{left:618px;bottom:320px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2k_161{left:618px;bottom:297px;letter-spacing:-0.02px;word-spacing:0.2px;}
#t2l_161{left:618px;bottom:273px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2m_161{left:618px;bottom:250px;letter-spacing:-0.16px;}
#t2n_161{left:700px;bottom:258px;letter-spacing:-0.01px;}
#t2o_161{left:724px;bottom:250px;letter-spacing:0.07px;word-spacing:0.11px;}
#t2p_161{left:618px;bottom:227px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2q_161{left:1145px;bottom:227px;}
#t2r_161{left:1161px;bottom:227px;}
#t2s_161{left:618px;bottom:204px;letter-spacing:0.15px;word-spacing:-0.64px;}
#t2t_161{left:618px;bottom:181px;letter-spacing:0.18px;word-spacing:-0.61px;}
#t2u_161{left:750px;bottom:181px;}
#t2v_161{left:765px;bottom:181px;letter-spacing:0.07px;word-spacing:-0.65px;}
#t2w_161{left:618px;bottom:157px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2x_161{left:618px;bottom:134px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t2y_161{left:618px;bottom:111px;letter-spacing:0.09px;word-spacing:0.09px;}
#t2z_161{left:898px;bottom:118px;}
#t30_161{left:904px;bottom:111px;letter-spacing:0.09px;word-spacing:0.1px;}
#t31_161{left:1063px;bottom:118px;letter-spacing:-0.01px;}
#t32_161{left:1087px;bottom:111px;letter-spacing:0.18px;word-spacing:0.01px;}
#t33_161{left:618px;bottom:88px;letter-spacing:0.07px;word-spacing:0.11px;}
#t34_161{left:618px;bottom:64px;letter-spacing:-0.07px;word-spacing:0.26px;}
#t35_161{left:768px;bottom:64px;}
#t36_161{left:783px;bottom:64px;letter-spacing:0.13px;word-spacing:0.05px;}
#t37_161{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_161{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_161{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_161{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_161{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_161{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_161{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_161{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_161{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts161" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg161Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg161" style="-webkit-user-select: none;"><object width="1210" height="935" data="161/161.svg" type="image/svg+xml" id="pdf161" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_161" class="t s0_161">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_161" class="t s1_161">© </span>
<span id="t3_161" class="t s0_161">(NCCN </span>
<span id="t4_161" class="t s1_161">© </span>
<span id="t5_161" class="t s0_161">), All rights reserved. NCCN Guidelines </span>
<span id="t6_161" class="t s1_161">® </span>
<span id="t7_161" class="t s0_161">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_161" class="t s2_161">NCCN Guidelines Version 4.2024 </span>
<span id="t9_161" class="t s2_161">Head and Neck Cancers </span>
<span id="ta_161" class="t s3_161">MS-20 </span>
<span id="tb_161" class="t s4_161">these data, high-dose cisplatin with RT is the preferred systemic </span>
<span id="tc_161" class="t s4_161">therapy/RT regimen for locally advanced SCCHN. However, if the clinician </span>
<span id="td_161" class="t s4_161">has a patient-specific concern about the toxicity of high-dose cisplatin, a </span>
<span id="te_161" class="t s4_161">weekly low-dose cisplatin regimen at a dose of 40 mg/m </span>
<span id="tf_161" class="t s5_161">2 </span>
<span id="tg_161" class="t s4_161">/week may be </span>
<span id="th_161" class="t s4_161">substituted. The categories of evidence for other perceived better tolerated </span>
<span id="ti_161" class="t s4_161">regimens are lower than for high-dose cisplatin. In the absence of </span>
<span id="tj_161" class="t s4_161">confirmatory and mature prospective comparison trials, it is unclear </span>
<span id="tk_161" class="t s4_161">whether weekly cisplatin is either less toxic or equally efficacious as high- </span>
<span id="tl_161" class="t s4_161">dose cisplatin. </span>
<span id="tm_161" class="t s4_161">Epidermal growth factor receptor (EGFR) overexpression is common in </span>
<span id="tn_161" class="t s4_161">SCCHN and is associated with poor survival outcomes. </span>
<span id="to_161" class="t s5_161">279,280 </span>
<span id="tp_161" class="t s4_161">Bonner et al </span>
<span id="tq_161" class="t s4_161">randomly assigned 424 patients with locally advanced stage III–IV </span>
<span id="tr_161" class="t s4_161">squamous cell carcinomas of the hypopharynx, oropharynx, and larynx to </span>
<span id="ts_161" class="t s4_161">receive definitive RT with or without cetuximab. </span>
<span id="tt_161" class="t s5_161">281 </span>
<span id="tu_161" class="t s4_161">Locoregional control </span>
<span id="tv_161" class="t s4_161">and median OS (49 vs. 29.3 months; </span><span id="tw_161" class="t s6_161">P </span><span id="tx_161" class="t s4_161">= .03) were significantly improved </span>
<span id="ty_161" class="t s4_161">in patients treated with RT and cetuximab compared to RT alone. Five- </span>
<span id="tz_161" class="t s4_161">year OS was 45.6% in patients treated with RT and cetuximab and 36.4% </span>
<span id="t10_161" class="t s4_161">in patients who received RT alone (HR, 0.73; 95% CI, 0.56–0.95; </span><span id="t11_161" class="t s6_161">P </span><span id="t12_161" class="t s4_161">= </span>
<span id="t13_161" class="t s4_161">.018). </span>
<span id="t14_161" class="t s5_161">282 </span>
<span id="t15_161" class="t s4_161">The randomized phase III RTOG 0522 trial showed that the addition of </span>
<span id="t16_161" class="t s4_161">cetuximab to cisplatin and RT did not significantly improve OS, compared </span>
<span id="t17_161" class="t s4_161">to cisplatin and RT, in patients with stage III or IV SCCHN and, </span>
<span id="t18_161" class="t s4_161">importantly, was more toxic. </span>
<span id="t19_161" class="t s5_161">283 </span>
<span id="t1a_161" class="t s4_161">In the phase III GORTEC 2007-01 trial, </span>
<span id="t1b_161" class="t s4_161">cetuximab combined with carboplatin/5-FU and RT was compared to </span>
<span id="t1c_161" class="t s4_161">cetuximab and RT. </span>
<span id="t1d_161" class="t s5_161">284 </span>
<span id="t1e_161" class="t s4_161">Three-year PFS (52.3% vs. 40.5%, respectively; </span>
<span id="t1f_161" class="t s4_161">HR, 0.73; 95% CI, 0.57–0.94; </span><span id="t1g_161" class="t s6_161">P </span><span id="t1h_161" class="t s4_161">= .015) and locoregional failure (21.6% </span>
<span id="t1i_161" class="t s4_161">vs. 38.8%, respectively; HR, 0.54; 95% CI, 0.38–0.76; </span><span id="t1j_161" class="t s6_161">P </span><span id="t1k_161" class="t s4_161">&lt; .001) rates </span>
<span id="t1l_161" class="t s4_161">were better with the cetuximab and carboplatin/5-FU regimen, but OS and </span>
<span id="t1m_161" class="t s4_161">distant metastases rates were not significantly improved. Grade 3 or 4 </span>
<span id="t1n_161" class="t s4_161">mucositis (73% vs. 61%, respectively; </span><span id="t1o_161" class="t s6_161">P </span><span id="t1p_161" class="t s4_161">= .014) and hospitalization for </span>
<span id="t1q_161" class="t s4_161">toxicity (42% vs. 22%, respectively; </span><span id="t1r_161" class="t s6_161">P </span><span id="t1s_161" class="t s4_161">&lt; .001) were more prevalent in </span>
<span id="t1t_161" class="t s4_161">patients who received cetuximab combined with carboplatin/5-FU and RT. </span>
<span id="t1u_161" class="t s4_161">Cetuximab combined with chemoradiation is not recommended as </span>
<span id="t1v_161" class="t s4_161">treatment for SCCHN. </span>
<span id="t1w_161" class="t s4_161">In three randomized phase III trials, cetuximab and RT was compared to </span>
<span id="t1x_161" class="t s4_161">cisplatin and RT as a deintensification treatment strategy for HPV-positive </span>
<span id="t1y_161" class="t s4_161">locally advanced oropharyngeal cancer. These trials showed that </span>
<span id="t1z_161" class="t s4_161">cetuximab and RT was inferior to cisplatin and RT (in terms of OS) and </span>
<span id="t20_161" class="t s4_161">was not better tolerated. </span>
<span id="t21_161" class="t s5_161">285,286 </span>
<span id="t22_161" class="t s4_161">In the RTOG 1016 non-inferiority trial, 849 </span>
<span id="t23_161" class="t s4_161">patients with locally advanced HPV-positive oropharyngeal cancer were </span>
<span id="t24_161" class="t s4_161">randomized to receive accelerated IMRT with either cetuximab or </span>
<span id="t25_161" class="t s4_161">cisplatin. </span>
<span id="t26_161" class="t s5_161">285 </span>
<span id="t27_161" class="t s4_161">After a median follow-up of 4.5 years, the cetuximab arm did </span>
<span id="t28_161" class="t s4_161">not meet the criterion for noninferiority (based on 5-year OS). Five-year </span>
<span id="t29_161" class="t s4_161">OS was 77.9% for the cetuximab arm and 84.6% for the cisplatin arm. </span>
<span id="t2a_161" class="t s4_161">PFS and risk of locoregional failure were significantly worse in the </span>
<span id="t2b_161" class="t s4_161">cetuximab arm compared to the cisplatin arm (HR, 1.72; 95% CI, 1.29– </span>
<span id="t2c_161" class="t s4_161">2.29; </span><span id="t2d_161" class="t s6_161">P </span><span id="t2e_161" class="t s4_161">&lt; .001 for PFS; HR, 2.05; 95% CI, 1.35–3.10; </span><span id="t2f_161" class="t s6_161">P </span><span id="t2g_161" class="t s4_161">&lt; .001 for </span>
<span id="t2h_161" class="t s4_161">locoregional failure). Five-year PFS and locoregional failure rates were </span>
<span id="t2i_161" class="t s4_161">67.3% and 17.3% for the cetuximab arm and 78.4% and 9.9% for the </span>
<span id="t2j_161" class="t s4_161">cisplatin arm, respectively. In the randomized phase III De-ESCALaTE </span>
<span id="t2k_161" class="t s4_161">HPV trial, cetuximab and RT was compared to cisplatin and RT in 334 </span>
<span id="t2l_161" class="t s4_161">patients with locally advanced p16-positive oropharyngeal squamous cell </span>
<span id="t2m_161" class="t s4_161">carcinoma. </span>
<span id="t2n_161" class="t s5_161">286 </span>
<span id="t2o_161" class="t s4_161">Patients given cisplatin and RT had significantly better 2- </span>
<span id="t2p_161" class="t s4_161">year OS (97.5% vs. 89.4%, respectively; HR, 5.0; 95% CI, 1.7–14.7; </span><span id="t2q_161" class="t s6_161">P </span><span id="t2r_161" class="t s4_161">= </span>
<span id="t2s_161" class="t s4_161">.001) and a lower recurrence rate (6.0% vs. 16.1%, respectively; HR, 3.4; </span>
<span id="t2t_161" class="t s4_161">95% CI, 1.6–7.2; </span><span id="t2u_161" class="t s6_161">P </span><span id="t2v_161" class="t s4_161">&lt; .001) compared to patients given cetuximab and RT. </span>
<span id="t2w_161" class="t s4_161">In the multicenter TROG 12.01 trial, 189 patients with intermediate-risk </span>
<span id="t2x_161" class="t s4_161">HPV-positive oropharyngeal cancer were randomized to receive 70 Gy RT </span>
<span id="t2y_161" class="t s4_161">with either weekly cisplatin (40 mg/m </span>
<span id="t2z_161" class="t s5_161">2 </span>
<span id="t30_161" class="t s4_161">/week) or cetuximab. </span>
<span id="t31_161" class="t s5_161">287 </span>
<span id="t32_161" class="t s4_161">The 3-year </span>
<span id="t33_161" class="t s4_161">failure-free survival was 93% in the RT/cisplatin arm and 80% in the </span>
<span id="t34_161" class="t s4_161">RT/cetuximab arm (</span><span id="t35_161" class="t s6_161">P </span><span id="t36_161" class="t s4_161">= .015). These three phase III trials demonstrated </span>
<span id="t37_161" class="t s7_161">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
